Actively Recruiting

Phase 1
Age: 18Years - 85Years
MALE
NCT06783829

A Study of SHR-4394 Injection in Subjects With Prostate Cancer

Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-02-27

240

Participants Needed

1

Research Sites

109 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.

CONDITIONS

Official Title

A Study of SHR-4394 Injection in Subjects With Prostate Cancer

Who Can Participate

Age: 18Years - 85Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male aged 18 to 85 years
  • ECOG physical condition score of 0-1
  • Expected survival of 6 months or longer
  • Histologically or cytologically confirmed prostate adenocarcinoma
  • At least one metastasis lesion present
  • Disease progression after the most recent prior treatment
  • Receiving continuous luteinizing hormone releasing hormone analogues or previous bilateral orchidectomy
  • Testosterone levels at castration range
  • Adequate organ function
Not Eligible

You will not qualify if you...

  • Received systemic anticancer treatments or investigational drugs within 4 weeks before study treatment start
  • Unresolved toxicities grade 2 or higher from previous anticancer therapy
  • History or symptoms of meningeal or central nervous system metastasis
  • Uncontrollable tumor-related pain
  • Uncontrolled pleural, pericardial, or abdominal effusion with symptoms
  • Other serious concomitant diseases
  • Previous or current other malignancies
  • History of severe allergic reactions to SHR-4394 or its ingredients
  • Active hepatitis B or C infection
  • Other conditions deemed inappropriate by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

West China Hospital of Sichuan University

Chengdu, Sichuan, China, 610041

Actively Recruiting

Loading map...

Research Team

Q

Qi Shi

CONTACT

Y

Yueling Wang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here